Should FOLFOXIRI plus bevacizumab be the standard first-line therapy in metastatic colorectal cancer?

Oncologist

Volumn 20, Issue 3, 2015, Pages 236-238

  Nipp, Ryan D ^a   Ryan, David P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; REGORAFENIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG RESPONSE; DRUG TARGETING; EDITORIAL; HUMAN; METASTATIC COLORECTAL CANCER; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; LIVER NEOPLASMS; MORTALITY; NEOPLASM METASTASIS; PATHOLOGY; SECONDARY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 84925459047     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0495     Document Type: Editorial

References (24)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104–117.
2. Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection andimprovedchemotherapy. JClinOncol2009;27: 3677–3683.
3. Tournigand C, Andre´ T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229–237.
4. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multi-center study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23:4866–4875.
5. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
6. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizu-mab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013–2019.
7. Hurwitz HI, Tebbutt NC, Kabbinavar F et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: Pooled analysis from seven randomized controlled trials. The Oncologist 2013; 18:1004–1012.
8. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408–1417.
9. Douillard JY, Siena S, Cassidy J etal. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic co-lorectal cancer: The PRIME study. J Clin Oncol 2010; 28:4697–4705.
10. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.
11. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311–1319.
12. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infu-sional fluorouracil, leucovorin, and irinotecan (FOL-FIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670–1676.
13. Loupakis F, Cremolini C, Masi G et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371:1609–1618.
14. Cremolini C, Loupakis F, Masi A et al. FOLFOX-IRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectalcancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group. J Clin Oncol 2015;33(suppl 3):657a.
15. Venook AP, Tabernero J. Progression-free survival: Helpful biomarker or clinically meaningless end point? J Clin Oncol 2015;33:4-6.
16. Shi Q, de Gramont A, Grothey A et al. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database. J Clin Oncol 2015;33:22-28.
17. Hutchins G, Southward K, Handley K et al. Valueof mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29:1261-1270.
18. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101:1642-1649.
19. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-1075.
20. Venook A, Niedzwiecki D, Lenz H-J. CALGB/ SWOG 80405: Phase III trial of irinotecan/5-FU/ leucovorin (FOLFIRI) oroxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum. J Clin Oncol 2014;32(5 suppl):LBA3a.
21. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-1389.
22. SEER Cancer Statistics Factsheets: Colon and RectumCancer. National Cancer Institute. Bethesda, MD. Available at http://seer.cancer.gov/statfacts/ html/colorect.html. Accessed January 31, 2015.
23. Moutinho C, Martinez-Cardus A, Santos C et al. Epigenetic inactivation of the BRCA1 interactor SRBCandresistancetooxaliplatin in colorectal cancer. J Natl Cancer Inst 2014;106:djt322.
24. Yang AD, Fan F, Camp ER et al.. Chronicoxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006;12:4147-4153.